Karyopharm Therapeutics Inc (NASDAQ:KPTI) insider Sharon Shacham sold 20,000 shares of the business’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $12.00, for a total value of $240,000.00.

KPTI stock traded down $0.40 during midday trading on Thursday, reaching $11.31. 22,953 shares of the company traded hands, compared to its average volume of 1,490,197. Karyopharm Therapeutics Inc has a 52-week low of $3.92 and a 52-week high of $19.19. The company has a debt-to-equity ratio of 1.46, a quick ratio of 6.93 and a current ratio of 6.93. The business has a 50 day moving average of $9.20 and a 200-day moving average of $6.66. The firm has a market capitalization of $733.76 million, a price-to-earnings ratio of -3.59 and a beta of 2.41.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.26. Karyopharm Therapeutics had a negative return on equity of 154.75% and a negative net margin of 2,138.80%. The business had revenue of $9.49 million for the quarter. Research analysts anticipate that Karyopharm Therapeutics Inc will post -3.64 earnings per share for the current year.

A number of hedge funds have recently modified their holdings of KPTI. Bank of Montreal Can purchased a new stake in Karyopharm Therapeutics during the second quarter valued at approximately $29,000. BNP Paribas Arbitrage SA raised its position in Karyopharm Therapeutics by 169,300.0% during the first quarter. BNP Paribas Arbitrage SA now owns 10,164 shares of the company’s stock valued at $59,000 after purchasing an additional 10,158 shares during the period. Envestnet Asset Management Inc. raised its position in Karyopharm Therapeutics by 12.4% during the second quarter. Envestnet Asset Management Inc. now owns 11,980 shares of the company’s stock valued at $72,000 after purchasing an additional 1,319 shares during the period. Parametric Portfolio Associates LLC purchased a new stake in Karyopharm Therapeutics during the second quarter valued at approximately $128,000. Finally, Premier Asset Management LLC purchased a new stake in Karyopharm Therapeutics during the second quarter valued at approximately $160,000. Institutional investors and hedge funds own 82.55% of the company’s stock.

A number of equities research analysts recently commented on KPTI shares. Wedbush boosted their target price on Karyopharm Therapeutics from $11.00 to $15.00 and gave the stock an “outperform” rating in a research report on Tuesday. ValuEngine upgraded Karyopharm Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, September 5th. BidaskClub upgraded Karyopharm Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, September 13th. HC Wainwright reiterated a “buy” rating and issued a $32.00 target price (up from $29.00) on shares of Karyopharm Therapeutics in a research report on Friday, July 5th. Finally, JPMorgan Chase & Co. upgraded Karyopharm Therapeutics from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $8.00 to $16.00 in a research report on Tuesday, July 23rd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Karyopharm Therapeutics has an average rating of “Buy” and an average price target of $17.89.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for
the treatment of cancer and other major diseases. Karyopharm’s SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1).

Read More: How the Consumer Price Index (CPI) is calculated?

Insider Buying and Selling by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.